RhumbLine Advisers
OKUR

RhumbLine Advisers’s OnKure Therapeutics OKUR Stock Holding History

RhumbLine Advisers’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.7K Buy
+20,996
New +$90.1K ﹤0.01% 3543
2024
Q3 		– Sell
-98
Closed -$1.48K – 4348
2024
Q2 		$1.48K Sell
98
-999
-91% -$16.9K ﹤0.01% 4207
2024
Q1 		$18.2K Buy
1,097
+38
+4% +$627 ﹤0.01% 3775
2023
Q4 		$16.9K Sell
1,059
-74
-7% -$4.61K ﹤0.01% 3794
2023
Q3 		$86.3K Buy
1,133
+323
+40% +$22K ﹤0.01% 3506
2023
Q2 		$53.2K Buy
+810
New +$65.3K ﹤0.01% 3667

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's OKUR Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 20,996 shares worth $95.7K. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in OKUR as recently as Q2 2024.

RhumbLine Advisers first reported a position in OKUR in Q2 2023 and has held it in 6 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • RhumbLine Advisers held 20,996 shares of OnKure Therapeutics worth $95.7K as of Q2 2026.
  • OnKure Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3543 holding.
  • RhumbLine Advisers first reported a position in OnKure Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.